Infectious bronchitis virus in Asia, Africa, Australia and Latin America: history, current situation and control measures

Wit, J. de; Cook, J. K. A.; Heijden, Hmjf van der

doi:10.1590/s1516-635x2010000200004

Cited by 15 publications

(7 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the virus exists as a wide range of antigenically and genetically distinct viral types, and the immune cross-protection offered by the different IBV serotypes is poor, making the prevention and control of this important pathogen both complex and challenging. Currently, over 50 different antigenic and genetic types of IBV are recognized, some of which have a substantial economic impact on the livestock industry and some of which are restricted to specific geographic areas (Capua et al, 1999;Wit et al, 2010). According to a new classification system based on the S1 gene phylogeny of IBV, six genotypes comprising 32 distinct viral lineages and a number of interlineage recombinants have been identified (Valastro et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Pathogenicity of a GI-22 genotype infectious bronchitis virus isolated in China and protection against it afforded by GI-19 vaccine

et al. 2019

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Pathogenicity of a GI-22 genotype infectious bronchitis virus isolated in China and protection against it afforded by GI-19 vaccine

et al. 2019

View full text Add to dashboard Cite

“…Multiple serotypes cocirculate in birds, which complicates diagnosis and control of IBV. High antigenic variation in the spike glycoprotein (S) is a hallmark of different IBV serotypes (1,7,8). Sequence difference, even as little as 4% in the S1 subunit of S protein, can lead to vaccine failure (9,10).…”

mentioning

confidence: 99%

A Novel Mucosal Adjuvant System for Immunization against Avian Coronavirus Causing Infectious Bronchitis

Chandrasekar

Kingstad-Bakke

et al. 2020

J Virol

View full text Add to dashboard Cite

Infectious Bronchitis (IB) caused by Infectious Bronchitis Virus (IBV) is currently a major threat to chicken health with multiple outbreaks being reported in the US over the past decade. Modified live virus (MLV) vaccines used in the field can persist and provide the genetic material needed for recombination and emergence of novel IBV serotypes. Inactivated and subunit vaccines overcome some of the limitations of MLV with no risk of virulence reversion and emergence of new virulent serotypes. However, these vaccines are weakly immunogenic and poorly protective. There is an urgent need to develop more effective vaccines that can elicit a robust, long-lasting immune response. In this study, we evaluate a novel adjuvant system developed from Quil-A and chitosan (QAC) for the intranasal delivery of nucleic acid immunogens to improve protective efficacy. The QAC adjuvant system forms nanocarriers (<100 nm) that efficiently encapsulate nucleic acid cargo, exhibit sustained release of payload and can stably transfect cells. Encapsulation of plasmid DNA vaccine expressing IBV nucleocapsid (N) protein by the QAC adjuvant system (pQAC-N) enhanced immunogenicity as evidenced by robust induction of adaptive humoral and cellular immune responses post vaccination and challenge. Birds immunized with pQAC-N showed reduced clinical severity and viral shedding post challenge on par with protection observed with current commercial vaccines without the associated safety concerns. Presented results indicate that the QAC adjuvant system can offer a safer alternative to the use of live vaccines against avian and other emerging coronaviruses. Importance According to the 2017 US agriculture statistics, the combined value of production and sales from broilers, eggs, turkeys, and chicks was $42.8 billion. Of this number, broiler sales comprised 67 percent of the industry value with the production of > 50 billion pounds of chicken meats. The economic success of the poultry industry in the USA hinges on the extensive use of vaccines to control Infectious Bronchitis Virus (IBV) and other poultry pathogens. Majority of vaccines currently licensed for poultry health include both modified live vaccine and inactivated pathogens. Despite their proven efficacy, modified live vaccine constructs take time to produce and could potentially revert to virulence, which limits their safety. The significance of our research stems from the development of a safer and potent alternative mucosal vaccine to replace live vaccines against IBV and other emerging coronaviruses.

show abstract

“…In addition the Iraqi strain (Sul/01/09) differs at 27-28% from the vaccine strains 4/91 and H120 used in the country [62]. It has been estimated that analysis of different parts of S1 protein can result in different level of homology [23], and there is increasing evidences that only a few amino acids differences amongst S protein are sufficient to have detrimental impact on cross protection [5,36]. In other viruses the difference in S protein as few as one or two amino acids as in the porcine transmissible gastroenteritis (TGEV) determine whether the virus is enteropathogenic or non-pathogenic in pigs [5,36].…”

Section: Fig 1: Similarity Between Vaccine Strains and Iraq Variant2 Strains (Test Strains )mentioning

confidence: 99%

“…In Iraq, IBV is highly prevalent and especially variant 2 sharing the other Middle East countries [20,21], vaccines are used (sometimes without official authorization) , and those are H120, H52,4/91, D274 . In all cases there is insufficient protection against IBV infections using conventional vaccine due to many reasons [1,22,23,24,25,26,27]. In addition, the use of vaccines especially the live attenuated type and in the presence of multiple infections with different IBV serotypes contributes to recombination process that favors the emergence of new IBV variants [28].…”

Section: Introductionmentioning

confidence: 99%

Untitled

2018

RJLBPCS

View full text Add to dashboard Cite

Infectious bronchitis disease is a contiguous disease in poultry, treated mainly by vaccination which is failed at high rate due to high variation of the Infectious Bronchitis Virus (IBV).Epitope -based vaccine as promising approach was used. In this study epitopes were derived from consensus sequence of vaccine strains used in Iraq, characterized and some of them docked with chicken MHC I molecules. Two B cell epitopes were obtained:51-59 (THTAQSGYY), 76-84(FMYGSYHPS) which satisfied the required criteria. Five CLT epitopes: 22-30 (TLELTNFTF), 57-65(GYYNFNFSF), 68-76(SFVYKESNF), 73-81(ESNFMYGSY), 99-107(NSLSVSLAY) were obtained according to acceptable criteria and docked very well with MHC I molecules of chickens .Six epitopes for helper T cell were obtained: 56-70(SGYYNFNFSFLSSFV), 57-71(GYYNFN FSFLSSFVY), 58-72(YYNFNFSFLSSFVYK), 61-75(FNFSFLSSFVYKESN) ,63-77(FSFLSSF VYKESNFM) ,64-78(SFLSSFVYKESNFMY), they react with many HLA alleles at high affinity.

show abstract

Infectious bronchitis virus in Asia, Africa, Australia and Latin America: history, current situation and control measures

Cited by 15 publications

References 85 publications

Pathogenicity of a GI-22 genotype infectious bronchitis virus isolated in China and protection against it afforded by GI-19 vaccine

Pathogenicity of a GI-22 genotype infectious bronchitis virus isolated in China and protection against it afforded by GI-19 vaccine

A Novel Mucosal Adjuvant System for Immunization against Avian Coronavirus Causing Infectious Bronchitis

Untitled

Contact Info

Product

Resources

About